TERN Terns Pharmaceuticals, Inc.
FY2024 10-K
Terns Pharmaceuticals, Inc. (TERN) filed its fiscal year 2024 10-K annual report with the SEC on Mar 20, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: clinical-stage biopharmaceutical developing small-molecule therapies for serious diseases including oncology (CML) and obesity
- • New emphasis on TERN-701 allosteric BCR-ABL inhibitor for CML with positive Phase 1 data and FDA orphan drug designation in March 2024
Management Discussion & Analysis
- • No revenue from product sales in FY 2024 and 2023; potential milestone revenue from TERN-701 license in Greater China
- • Net loss $88.9M in 2024 vs $90.2M in 2023; operating expenses $101.9M vs $102.6M; R&D expenses rose 10% to $70.1M, G&A expenses decreased 19% to $31.8M
Risk Factors
- • Regulatory risk: compliance with Section 404 of Sarbanes-Oxley Act may cause significant costs and penalties
- • Macroeconomic threat: global economic downturn may weaken demand and delay payments for potential approved drugs
Financial SummaryXBRL
Net Income
-$89M
ROE
-25.7%
Total Assets
$364M
EPS (Diluted)
$-1.12
Operating Cash Flow
-$70M
Source: XBRL data from Terns Pharmaceuticals, Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Terns Pharmaceuticals, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.